If we look at who the major shareholders are, we find that insiders hold 58.86% of Entasis Therapeutics Holdings Inc. shares while 30.95% of the shares are in the hands of institutional holders. This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the timing of the initiation, progress and scope of the Phase 3 clinical trial of ETX2514SUL, the potential use of ETX2514SUL to treat a variety of serious multidrug-resistant infections caused by Acinetobacter baumannii, Entasis’ potential receipt of milestone payments and royalties from Zai Lab. In China, A. baumannii accounts for approximately 11% of total Gram-negative infections. due by 20 March 2022, for ENTASIS THERAPEUTICS LIMITED (09475809), 82990 - Other business support service activities not elsewhere classified, Companies House does not verify the accuracy of the information filed. Collaboration will facilitate enrollment of pivotal global Phase 3 trial of ETX2514 in combination with sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii infections. Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Sulbactam is a generic β-lactam that has intrinsic activity against A. baumannii but suffers from widespread β-lactamase-mediated resistance. — Ruben Tommasi, Chief Scientific Officer ©2021 Entasis Therapeutics Inc. — Ruben Tommasi, Chief Scientific Officer ©2021 Entasis Therapeutics Inc. Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com. Final gross price and currency may vary according to local VAT and billing address. Entasis Therapeutics' mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. Entasis Forward-looking Statements Based on a national surveillance of over 1,300 hospitals in China, there are over 200,000 A. baumannii infections per year, although the actual incidence is estimated to be much larger. We are thrilled to partner with Zai Lab on the further development and potential commercialization of ETX2514SUL in the Asia-Pacific region, most notably in Greater China, where the rate of A. baumannii infections rank among the highest in the world,” said Manos Perros, Chief Executive Officer of Entasis. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Solebury Trout John Graziano +1 646 378 2942 Next accounts made up to 31 December 2020 31 December 2019, Next statement date 6 March 2022 Rice, MD is the Chairman of the Department of Medicine, Joukowsky Family Professor of Medicine, and Professor of Molecular Microbiology & Immunology at the Warren Alpert Medical School of Brown University, and the Physician-in-Chief of Medicine at Rhode Island Hospital and The Miriam Hospital in Providence, RI. 30 September 2021, Last accounts made up to The Entasis Therapeutics Holdings stock forecast is 0 USD for 2022 March 14, Monday with technical analysis. The company's File Number is listed as 5707549. We expect ETX2514SUL will be a positive addition to Zai Lab ’s anti-infective portfolio, and we remain committed to developing a drug to combat multidrug-resistance, which currently poses a serious global threat to our society,” stated Samantha Du, Ph.D., Chairman and Chief Executive Officer of Zai Lab. — Ruben Tommasi, Chief Scientific Officer ©2021 Entasis Therapeutics Inc. Kyle Dow Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. MacDougall Biomedical Communications WALTHAM, Mass. You can change your cookie settings at any time. Want to receive periodic news about Entasis’ progress? +86 21 6163 7322billy.cho@zailaboratory.com, Solebury Trout At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections." Entasis Therapeutics Holdings (ETTX) stock price prediction is 0 USD. WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused … Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced that members of management will participate in A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19th, 2020. To accept or reject analytics cookies, turn on JavaScript in your browser settings and reload this page. John Graziano Except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. Media Contact Annika Parrish The Ruth Group (508) 280-6592 aparrish@theruthgroup.com. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Subscribe to our news wire by filling out the confidential sign-up form below. Entasis Therapeutics. WALTHAM, Mass. About Entasis Get Entasis Therapeutics company's verified web address, revenue, total contacts 13, industry Healthcare, Pharmaceuticals, & Biotech and location at Adapt.io Investor Relations Contact James Salierno The Ruth Group (646) 536-7035 / (646) 536-7028 jsalierno@theruthgroup.com. “This collaboration reinforces the strength of the Zai Lab team both in China and globally, and we believe will help us further progress on our mission to establish Zai Lab as an innovative, fully integrated, global pharmaceutical company.”. The U.S. Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to ETX2514SUL for the treatment of hospital-acquired and ventilator-acquired bacterial pneumonia and bloodstream infections due to A. baumannii. The collaboration will offset costs and enable enrollment of patients from China into our global Phase 3 clinical trial, further supporting our plans to rapidly progress ETX2514SUL to market.”, “Infectious diseases are a key focus area for Zai Lab due to the serious problem of multidrug-resistant infections both in China and globally. We use cookies to make our services work and collect analytics information. Entasis Company Contact Under the terms of the agreement, Entasis has granted Zai Lab an exclusive license to develop and commercialize ETX2514SUL in specified countries in the Asia-Pacific region, including Japan. ENTASIS THERAPEUTICS LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity Wall Street Stock Market & Finance report, prediction for the future: You'll find the Entasis Therapeutics Holdings share forecasts, stock quote and buy / sell signals below.According to present data Entasis Therapeutics Holdings's ETTX shares and potentially its … Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. (781) 235-3060kwatson@macbiocom.com or stuck@macbiocom.com, ZAI LAB CONTACTS: Just enter your email address below. Entasis Therapeutics Inc. is a Delaware Corporation filed on March 11, 2015. baumannii is a Gram-negative bacterium causing severe infections associated with high mortality and has emerged as a cause of numerous global outbreaks, displaying ever-increasing rates of antibiotic resistance, which greatly limits treatment options. We are excited to collaborate with Entasis, a company that has extensive expertise and know-how in developing anti-infective products that address multidrug-resistant infections, and we look forward to working together to accelerate the global development of this potential life-saving therapy. LeadCandy provides Full Profile, verified Email Address, Social Profile links, and Mutual Contacts of Entasis Therapeutics employees. Entasis’ ETX2514 is a novel broad-spectrum intravenous inhibitor of β-lactamases, which are a major cause of antibiotic resistance. Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com. Source: Entasis Therapeutics Holdings Inc. The Registered Agent on file for this company is The Corporation Trust Company and is located at Corporation Trust Center 1209 Orange St, Wilmington, DE 19801. “Entasis remains committed to building a pipeline of life-saving treatments for patients affected by drug-resistant bacterial infections around the world. Company Contact: Entasis Therapeutics Chris White, 781-810-0114 or Media Contact: MacDougall Biomedical Communications Julia Ogier, 781-235-3060 JOgier@macbiocom.com Along with industry partners, academia and regulators, Entasis Therapeutics is committed to the concept of streamlined development programs focused on pathogen-directed antibacterials that may target only a single species of highly resistant bacterial pathogens in areas of high unmet medical need. Entasis Therapeutics Holdings Inc () Stock Market info Recommendations: Buy or sell Entasis Therapeutics Holdings stock? Source: Entasis Therapeutics Holdings Inc. Media Contact Kirsten Thomas The Ruth Group (508) 280-6592 kthomas@theruthgroup.com. Samir MOUSSA, Prinicipal Scientist | Cited by 390 | of Entasis therapeutics, Massachusetts | Read 24 publications | Contact Samir MOUSSA Kari Watson or Stefanie Tuck Web www.entasistx.com. Local Business. Consequently, the World Health Organization (WHO) has placed carbapenem-resistant A. baumannii at the top of its list of “Critical” priority pathogens for new antibiotics. Zai Lab We use some essential cookies to make our services work. Zai Lab will manage the portion of the Phase 3 trial conducted in China. For more information, visit www.entasistx.com. We have assembled a world-class team with a global calling to work on these life-saving, long lasting antibacterial therapies. Entasis' clinical pipeline includes a combination medicine candidate in Phase III (sulbactam/durlobactam) that targets Carbapenem-resistant A. baumannii (CRAB); a compound in Phase I (ETX0282/cefpodoxime) that targets CRE; and zolifloadacin** in Phase II, being developed with GARDP and that targets N. … Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Zai Lab’s filings with the Securities and Exchange Commission. ** None Business Development/Partnerships Investor Relations Human Resources … Billy Cho See the full list at Craft. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide. Phone +1-781-8100120. Entasis is developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of a variety of serious multidrug-resistant infections caused by Acinetobacter baumannii, representing a healthcare challenge of global importance with over 200,000 occurrences estimated in China each year. You can identify forward-looking statements because they contain words such as “believes” and “expects.” Forward-looking statements are based on Zai Lab’s current expectations and assumptions. In addition, Entasis and Zai Lab have an option to collaborate on the development and commercialization of ETX2514 in combination with other active ingredients. You've rejected analytics cookies. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and global unmet medical needs. These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. A joint steering committee will be formed between the companies to oversee development, regulatory and commercialization activities in the Asia-Pacific territory. Contact Us. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections." Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis Therapeutics is working to discover, develop and commercialize safe and effective novel molecules that address and overcome mechanisms of antibiotic resistance in … We'd also like to use analytics cookies so we can understand how you use our services and to make improvements. Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)’s Major holders. Zai Lab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. — September 28, 2017 — Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced the presentation of data on … At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections." You've accepted analytics cookies. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae). ETX2514 restores the in vitro activity of multiple β-lactams against Gram-negative, multidrug-resistant pathogens. See more of Entasis Therapeutics on Facebook. ETX2514 has completed single- and multi-ascending dose Phase 1 trials. due by “With their experienced leadership team, focus on innovation and established expertise and network within the infectious diseases arena, Zai Lab is the ideal partner to help bring ETX2514SUL to the numerous patients in the region who need a new effective treatment option. Investor Relations Contacts James Salierno The Ruth Group (646) 536-7028 jsalierno@theruthgroup.com. Louis B. Forward-looking statements contained in this press release include statements about (i) the timing of the initiation, progress and scope of the Phase 3 clinical trial of ETX2514SUL; (ii) potential regulatory approval and commercialization of ETX2514SUL; (iii) the potential use of ETX2514SUL to treat a variety of serious multi-drug resistant infections caused by Acinetobacter baumannii; and (iv) Entasis’ potential receipt of milestone payments and royalties. (781) 810-0114kyle.dow@entasistx.com, Entasis Media Contact Log In Entasis is initially developing ETX2514SUL, a fixed-dose combination of ETX2514 and sulbactam, for the treatment of a variety of serious multidrug-resistant infections caused by A. baumannii. The U.S. Centers for Disease Control (CDC) also recognizes A. baumannii as a serious public health threat and estimates that 63% of A. baumannii are multidrug-resistant. Find 12 researchers and browse 1 departments, publications, full-texts, contact details and general information related to Entasis therapeutics | Waltham, United States | Fax 302-6555049. The ratio of debt to operating expenses for Entasis Therapeutics Holdings Inc is higher than it is for about only 5.61% of US stocks. ETX2514SUL is currently in Phase 2 development with plans to move into global Phase 3 clinical trials in the first quarter of 2019. The resistance of A. baumannii to the carbapenem class of antibiotics has increased significantly, estimated at 60% in 2016, with some provinces as high as 70-80%. About Zai Lab Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition. Meet Entasis Therapeutics' Scientific and Clinical Board. About ETX2514 Entasis Media Contact Kari Watson or Stefanie Tuck MacDougall Biomedical Communications (781) 235-3060 kwatson@macbiocom.com or stuck@macbiocom.com. Due to the high rates of multidrug-resistant infections, the Chinese government has identified the goal of developing one to two innovative anti-infective drugs by 2020. ETTX Stock Summary. Find people working at Entasis Therapeutics. +1 646 378 2942jgraziano@troutgroup.com, Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514. 100917_Entasis IDWeek ETX2514 Abstract PR FINALFDA grants Qualified Infectious Disease Product (QIDP) and Fast Track designation to ETX2514SUL, the combination of ETX2514 with sulbactam. In preclinical studies, ETX2514 restored sulbactam antibacterial activity against A. baumannii. John Mueller is Chief Development Officer for Entasis Therapeutics Holdings, Inc. and Chief Development Officer of Entasis Therapeutics, Inc. Comment Guidelines The share float percentage for the stock currently stands at 75.22%. You can change your cookie settings at any time. I am contacting Entasis about Required. Entasis Therapeutics Holdings Inc's stock had its IPO on September 26, 2018, making it an older stock than only 4.39% of US equities in our set. Entasis Therapeutics is headquartered in Waltham, MA and has 1 office location across 1 country. Entasis and Zai Lab will cooperate in conducting a pivotal Phase 3 trial in China, with Zai Lab taking the lead by conducting the screening, enrollment and treatment of patients, and coordinating development, registration and commercialization of ETX2514SUL in the territory. Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com. About Acinetobacter baumannii InfectionsA. Entasis Therapeutics ZAI LAB CONTACTS: Zai Lab Billy Cho +86 21 6163 7322 billy.cho@zailaboratory.com. Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Actual results may differ materially from these forward-looking statements. ETX2514 is a novel broad-spectrum intravenous inhibitor of class A, C and D beta-lactamases. and SHANGHAI, April 25, 2018 – Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, and Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced an exclusive license agreement for ETX2514 in the Asia-Pacific region and a global strategic development collaboration. The company can be reached via phone at 781-810-0120 or via email at [email protected] This page was last updated on 3/17/2021 by MarketBeat.com Staff Zai Lab Forward-Looking Statements (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices) Securities registered pursuant to Section 12(b) of the Act: Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sc… Address Waltham, MA 02451-1215 United States. In addition to financial support for the portion of the Phase 3 trial conducted in China, Entasis will receive a $5 million upfront payment and is eligible to receive up to an aggregate of $7.6 million in near-term development milestones and up to an aggregate of $91.0 million in additional development, regulatory and sales milestone payments related to ETX2514SUL and other combinations, plus royalties. In other Asia-Pacific countries, such as Japan and Korea, it has also become an increasingly significant challenge for physicians.
Corona-verordnung Gastronomie Baden-württemberg,
Susan Sarandon Friends,
Ocean View Pismo Beach,
Grand Hotel Trento,
Badische Zeitung Bad Säckingen Heute,